Posted inBiotechnology
Cognition’s phase 2 SHIMMER results finally allow dementia drug to shine
The failure of Cognition Therapeutics’ Alzheimer’s disease candidate CT1812 in the SHINE trial earlier this year may have rubbed off…
Posted inBiotechnology
Novo Nordisk taps Photys for $186M cardiometabolic collab
With Novo Nordisk’s name already synonymous with treatments for diabetes and obesity, the Danish drugmaker has been making a concerted…
Posted inBiotechnology
Novo Holdings leads SiteOne’s $100M series C for non-opioid pain treatments
SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target the peripheral…
Posted inBiotechnology
Sanofi, Teva look to ‘next frontier’ in IBD treatment after TL1A antibody hits mark in midstage trial
As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and Teva…
Posted inBiotechnology
Biomea’s diabetes drug improves glucose control 3 months after FDA hold lifted
Three months after Biomea Fusion’s menin inhibitor was released from a clinical hold, the company has claimed a win in…
Posted inBiotechnology
Cash-strapped Portage finds hope in sale of lead asset, subsidiary to Immunova
After spending most of the year hunting for options to stay afloat, cash-strapped Portage Biotech appears to have found salvation…
Posted inBiotechnology
Fresh off $120M raise, AI-powered Terray is teaming up with Gilead in multi-pronged R&D pact
Terray is ending the year on a high. Just two short months ago the biotech came out with a healthy…
Posted inBiotechnology
Fierce Biotech’s top 10 editor’s picks for 2024
The year kicked off with a flurry of dealmaking at the J.P. Morgan Healthcare Conference in January, and the pace…
Posted inBiotechnology
Merck drops TIGIT asset and LAG-3 program, discontinuing several phase 3 trials
Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline…
Posted inBiotechnology
UCB’s orchestra hits dud note: Novartis-partnered Parkinson’s asset fails phase 2
UCB’s Novartis-partnered investigational small molecule has failed to improve symptoms of Parkinson’s disease in a phase 2a trial. The oral…